C18 Ganglioside GD3-d3
目录号 : GC46991
A neuropeptide with diverse biological activities
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
C18 Ganglioside GD3-d3 is intended for use as an internal standard in the quantification of ganglioside GD3 by GC- or LC-MS. Ganglioside GD3 is synthesized by the addition of two sialic acid residues to lactosylceramide and can serve as a precursor to the formation of more complex gangliosides by the action of glycosyl- and sialyltransferases. With roles in cell proliferation and differentiation, its expression increases during development and in pathological conditions such as cancer.1 Furthermore, the intracellular accumulation of ganglioside GD3 can contribute to mitochondrial damage, a crucial event during apoptosis.2 Ganglioside GD3 has become a target for therapeutic approaches to prevent malignant properties of tumor cells like melanoma.1,3 [Matreya, LLC. Catalog No. 2054]
1.Hamamura, K., Furukawa, K., Hayashi, T., et al.Ganglioside GD3 promotes cell growth and invasion through p130Cas and paxillin in malignant melanoma cellsProc. Natl. Acad. Sci. U.S.A.102(31)11041-11046(2005) 2.De Maria, R., Lenti, L., Malisan, F., et al.Requirement for GD3 ganglioside in CD95- and ceramide-induced apoptosisScience277(5332)1652-1655(1997) 3.Nicoll, G., Avril, T., Lock, K., et al.Ganglioside GD3 expression on target cells can modulate NK cell cytotoxicity via siglec-7-dependent and -independent mechanismsEur. J. Immunol.33(6)1642-1648(2003)
| Cas No. | N/A | SDF | |
| Canonical SMILES | OC[C@H]1O[C@@H](OC[C@H](NC(CCCCCCCCCCCCCCCCC([2H])([2H])[2H])=O)[C@H](O)/C=C/CCCCCCCCCCCCC)[C@H](O)[C@@H](O)[C@@H]1O[C@]2([H])O[C@H](CO)[C@H](O)[C@H](O[C@@]3(C(O)=O)O[C@@H]([C@H](O)[C@H](O[C@@]4(C(O)=O)O[C@@H]([C@H](O)[C@@H](CO)O)[C@H](NC(C)=O)[C@@H](O)C4)CO)[C@H](NC(C)=O)[C@@H](O)C3)[C@H]2O | ||
| 分子式 | C70H122D3N3O29 | 分子量 | 1475.8 |
| 溶解度 | Chloroform:Methanol:Water (2:1:0.1): Soluble | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.6776 mL | 3.388 mL | 6.776 mL |
| 5 mM | 0.1355 mL | 0.6776 mL | 1.3552 mL |
| 10 mM | 0.0678 mL | 0.3388 mL | 0.6776 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。